ORGANOGENESIS' LOSS DEEPENSOrganogenesis Inc. (NASDAQ:ORG) of Cambridge, Mass., said thatduring the fourth quarter the company expanded its Testskinproduct line into new markets and introduced its new Genesisproduct line.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent changeRevenues $863 943 -8Net income (loss) (1,700) (1,400) -21Net income per share (loss) (.24) (.22) -9

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,596 3,598 0Net income (loss) (6,100) (4,300) -42Net income per share (loss) (.88) (.68) -29

ENZON INCREASES REVENUES

Enzon Inc. (NASDAQ:ENZN) of South Plainfield, N.J. GailWasilewski, the company's vice president of finance, saidsecond-quarter results reflect an increase in researchpersonnel and drugs used for clinicals. The company's researchand development costs increased during the second quarter by$434,000, or 26 percent, compared with the same period lastyear, the company said. Other general and administrative costsrose 40 percent to $1.7 million from $1.2 million during thesame period last year. Revenues for the year included sales forAdagen, which was launched in October 1990, the companysaid.

Second quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $808 16 +4,950Operating income (loss) (3,324) (2,835) -17Net income (loss) (2,938) (2,700) -9Net income per share (loss) (.22) (.22) 0Outstanding shares 13,580 12,352 +10

DNA PLANT TECHNOLOGY DOUBLES LOSS

DNA Plant Technology (NASDAQ:DNAP) of Cinnaminson, N.J.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,148 3,228 -2Net income (loss) (3,113) (1,017) -206Net income per share (loss) (.15) (.05) -200Outstanding shares 20,846 20,685 neg.

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $13,427 12,890 -4Net income (loss) (8,939) (2,948) -203Net income per share (loss) (.43) (.14) -207Outstanding shares 20,801 20,676 neg.

QUEST DEEPENS NET LOSS

Quest Biotechnology Inc. (NASDAQ:QBIO) of Detroit said thatduring the fourth quarter it acquired approximately 35 percentof AM Diagnostics Inc.'s common stock pursuant to thereorganization and recapitalization of AM Diagnostics. Quest hasthe option, after certain conditions are met, to purchase 100percent of the common stock of Nippon Monitor K.K., AMDiagnostics' Japanese subsidiary.

Fourth quarter ended Oct. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $223 233 -4Operating income (loss) (43) 1 n/aNet income (loss) (77) (1) n/aNet income per share (loss) (.03) -- n/aOutstanding shares 2,391 2,391 0

Year ended Oct. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $476 738 -35Operating income (loss) (516) (345) -50Net income (loss) (408) (348) -17Net income per share (loss) (.17) (.15) -13Outstanding shares 2,391 2,317 neg.

IMMUNE RESPONSE INCREASES REVENUES

Immune Response Corp. (NASDAQ:IMNR) of San Diego.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $1,089 936 +251Net income (loss) (1,639) (1,663) +1Net income per share (loss) (.15) (.22) +32Outstanding shares 11,002 7,438 +35

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $4,284 3,316 +130Net income (loss) (1,240) (4,661) +73Net income per share (loss) (.12) (.63) +81Outstanding shares 9,939 7,366 +35

(c) 1997 American Health Consultants. All rights reserved.

No Comments